
Statins are cholesterol-lowering medicines used to reduce the risk of heart attack, ischemic stroke, and other complications of atherosclerosis. They work mainly by lowering LDL cholesterol, the major cholesterol-carrying particle involved in plaque formation. For people at high cardiovascular risk, the benefit can be substantial; for people at low risk, the decision is more individualized because the absolute benefit is smaller.
The main statins include atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, pitavastatin, and fluvastatin. They differ in potency, dose, metabolism, and drug interactions, but they all target the same liver enzyme involved in cholesterol production. Most people tolerate statins well. Muscle symptoms are the most discussed side effect, while severe muscle injury is rare. Statins can also slightly increase blood sugar in some people and can raise liver enzymes, especially at higher doses. The right question is not simply whether statins are “good” or “bad,” but whether your expected cardiovascular benefit outweighs the risks and inconvenience for you.
Table of Contents
- How Statins Work and How Much They Lower LDL
- Benefits for Heart Attack and Stroke Prevention
- Who Should Take a Statin
- Side Effects and Safety
- Choosing the Right Statin and Dose
- Monitoring, Lifestyle, and Follow-Up
- Questions to Ask Before Starting or Stopping
How Statins Work and How Much They Lower LDL
Statins block HMG-CoA reductase, an enzyme the liver uses to make cholesterol. In response, liver cells place more LDL receptors on their surface. Those receptors remove LDL particles from the bloodstream, so circulating LDL cholesterol falls.
The amount of LDL reduction depends mostly on the drug and dose. Clinicians group statin regimens by expected intensity:
- High-intensity statins generally lower LDL by 50% or more. Common examples are atorvastatin 40–80 mg and rosuvastatin 20–40 mg daily.
- Moderate-intensity statins generally lower LDL by about 30% to 49%. Examples include atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg, and several doses of pravastatin or pitavastatin.
- Low-intensity regimens lower LDL by less than 30% and are used less often when substantial risk reduction is needed.
These are expected averages, not guarantees. If LDL is 160 mg/dL, a 50% reduction would bring it to roughly 80 mg/dL, while a 35% reduction would bring it to about 104 mg/dL. Genetics, adherence, baseline diet, other medicines, and individual biology can shift the result.
LDL is not the only lipid measurement that matters. Non-HDL cholesterol and ApoB testing can provide additional information about atherogenic particles in selected patients, particularly when triglycerides are elevated, diabetes is present, or LDL has already been driven very low.
The 2026 U.S. dyslipidemia guideline again uses both percentage LDL reduction and absolute LDL goals. In broad terms, higher cardiovascular risk calls for a lower target. Borderline- or intermediate-risk primary-prevention patients who receive lipid-lowering treatment often have an LDL goal below 100 mg/dL; high-risk primary prevention generally targets below 70 mg/dL. Most people with very high-risk established atherosclerotic cardiovascular disease have a goal below 55 mg/dL.
Benefits for Heart Attack and Stroke Prevention
The strongest reason to take a statin is not to improve a laboratory report. It is to lower the chance that an atherosclerotic plaque will cause a heart attack, ischemic stroke, or another vascular event.
Large randomized trials and systematic reviews consistently show that statins reduce major cardiovascular events. The relative benefit tends to track with the amount of LDL reduction, while the absolute benefit depends heavily on baseline risk. That distinction explains why the same statin can be essential for one person and optional for another.
Imagine two people who each receive a treatment that reduces their relative risk by about 25%. If one has a 20% untreated chance of an event over a given period, a 25% relative reduction lowers that risk to about 15%, an absolute reduction of 5 percentage points. If another person starts at only 4% risk, the same relative reduction lowers risk to about 3%, an absolute change of 1 point. Both benefit, but the first person prevents more events per number of people treated.
For secondary prevention—people who already have clinical atherosclerotic cardiovascular disease—the benefit is usually clear. This group includes many people with a previous myocardial infarction, ischemic stroke or transient ischemic attack caused by atherosclerosis, symptomatic peripheral artery disease, or prior coronary revascularization. Statins are foundational treatment unless there is a compelling reason they cannot be used.
For primary prevention, treatment is based on future risk rather than a previous event. Current U.S. guidance uses the PREVENT-ASCVD equations in adults ages 30 to 79 to estimate 10- and 30-year risk, then combines that estimate with LDL level and personal risk factors. Coronary artery calcium can sometimes refine an uncertain decision; a coronary artery calcium score can show whether calcified coronary plaque is already present.
Statins also matter because atherosclerosis develops over decades. Lowering exposure to atherogenic lipoproteins earlier can reduce cumulative artery damage. That is why modern guidelines increasingly consider lifetime and 30-year risk rather than waiting until a person’s 10-year risk becomes high late in life.
Who Should Take a Statin
Statin decisions are individualized, but several groups commonly have strong indications because their expected benefit is high.
People with established atherosclerotic cardiovascular disease
A statin is generally recommended after a heart attack, for chronic coronary disease, many ischemic strokes, symptomatic peripheral artery disease, and other forms of clinical atherosclerosis. High-intensity or maximally tolerated statin therapy is often used, with nonstatin treatment added when LDL remains above goal.
People with very high LDL
An untreated LDL of 190 mg/dL or higher strongly suggests severe primary hypercholesterolemia and sometimes familial hypercholesterolemia. These patients usually need medication regardless of a short-term risk calculator because lifelong LDL exposure is high. Anyone with this degree of elevation should also be evaluated for secondary causes and family history. See causes and treatment of high LDL cholesterol for the broader workup.
Many adults with diabetes, chronic kidney disease, or HIV
Current U.S. guidance identifies several conditions in which statin therapy may be indicated without relying only on a standard risk estimate. Diabetes, chronic kidney disease, and HIV can raise atherosclerotic risk in ways that a simple cholesterol number does not capture. The exact statin intensity still depends on age, overall risk, kidney function, interactions, and other factors.
Adults whose calculated risk justifies treatment
For adults without the conditions above, PREVENT-ASCVD risk estimation can guide the discussion. The 2026 guideline considers lipid-lowering therapy reasonable at a borderline 10-year risk of 3% to less than 5% and recommends stronger consideration at intermediate risk of 5% to less than 10%, after a clinician-patient discussion. High risk at 10% or more generally supports more intensive LDL lowering.
Risk-enhancing details can move the decision. Examples include a strong family history of premature cardiovascular disease, elevated lipoprotein(a), persistently high triglycerides, certain higher-risk ancestry, inflammatory conditions, or evidence of subclinical plaque. The decision is not generated by one calculator alone.
Older adults deserve individualized assessment. Age raises cardiovascular risk, but frailty, life expectancy, medication burden, function, and patient goals affect how much benefit can realistically be achieved. Current guidance supports considering moderate-intensity statin initiation in selected adults age 75 or older when life expectancy and health status make prevention meaningful, rather than using age alone as a reason to start or stop.
Side Effects and Safety
Most people can take statins without major problems. The safety discussion should separate common symptoms from rare serious events and should compare treatment risk with the cardiovascular risk of leaving LDL untreated.
Muscle symptoms
Aches, soreness, cramps, heaviness, or weakness are the most common complaints attributed to statins. These symptoms are often called statin-associated muscle symptoms, or SAMS. They may occur with normal CK levels, and there is no single test that proves an ordinary ache came from a statin.
Blinded trials suggest that the excess of muscle symptoms directly caused by statins is smaller than the number reported in routine care. Some symptoms occur coincidentally, while expectations about side effects can influence symptom perception. Still, genuine statin muscle effects occur and deserve evaluation rather than dismissal.
Serious muscle breakdown, or rhabdomyolysis, is rare. Severe weakness, very intense muscle pain, dark urine, or symptoms after a major drug interaction require prompt evaluation. A structured review of statin muscle pain can help distinguish ordinary soreness from a problem that requires a treatment change.
Blood sugar and diabetes
Statins can slightly increase blood glucose and the risk of new-onset diabetes, with a stronger signal at higher-intensity treatment and in people already prone to diabetes. This risk is usually outweighed by cardiovascular benefit when a statin is clearly indicated. A person with prediabetes should generally focus on weight, activity, diet, sleep, and glucose monitoring rather than avoiding an indicated statin solely because of this possibility.
Liver effects
Mild liver-enzyme elevations can occur. Clinically serious liver injury is rare. Clinicians usually obtain liver tests when starting therapy or when symptoms or medical history warrant them, rather than repeatedly testing everyone without a reason. Seek medical advice for unexplained jaundice, dark urine with pale stools, or severe persistent abdominal symptoms.
Other concerns
Statins have been blamed for many conditions, including memory loss and generalized fatigue. High-quality evidence has not established a broad pattern of major cognitive harm from statin therapy. Individual symptoms still deserve attention, especially when they begin soon after a dose change and improve with withdrawal.
Pregnancy is a special situation. Lipid-lowering treatment decisions should be reviewed before conception and during pregnancy because routine statin use is generally avoided in pregnancy, with exceptions requiring specialist judgment for very high-risk conditions.
Choosing the Right Statin and Dose
The “best” statin is the one that achieves the needed LDL reduction with acceptable safety, interactions, cost, and tolerability. Potency matters, but so do the rest of your medicines and your previous experience.
Atorvastatin and rosuvastatin are commonly chosen when a large LDL reduction is needed because they can be used at high intensity. Pravastatin and pitavastatin have different metabolic profiles and may be useful when drug interactions or tolerability are concerns. Simvastatin remains effective but has more dose- and interaction-related limitations than some newer choices.
Your clinician may select a lower starting dose if you are older, frail, have kidney or liver impairment, take interacting medicines, or previously developed muscle symptoms. A lower dose is not automatically inadequate; it depends on the LDL target. In some people, a moderate statin plus a nonstatin medicine reaches the goal with fewer side effects than forcing the highest tolerated statin dose.
If one statin causes symptoms, that does not prove every statin will. Professional guidance generally recommends trying another statin, a lower dose, or a different schedule before declaring complete intolerance. People who truly cannot tolerate enough statin therapy have effective options including ezetimibe, bempedoic acid, and PCSK9-targeting drugs. A comparison of statin alternatives explains when those medicines are used.
Medication interactions deserve special attention. Some antibiotics, antifungals, HIV medicines, transplant drugs, and other medications can raise statin concentrations. Grapefruit also interacts with certain statins. Always tell the prescriber and pharmacist about supplements and short-term prescriptions, not just your daily medicines.
Monitoring, Lifestyle, and Follow-Up
A statin works best as part of a risk-reduction plan, not as permission to ignore food, activity, smoking, blood pressure, or diabetes. Lifestyle changes can lower LDL further and improve cardiovascular health through mechanisms beyond cholesterol.
A heart-supportive eating pattern emphasizes vegetables, fruit, legumes, whole grains, nuts, seeds, fish or other lean proteins, and unsaturated fats while limiting excess saturated fat, trans fat, refined carbohydrates, and highly processed foods. Increasing soluble fiber for cholesterol can provide an additional modest LDL reduction. Regular exercise improves fitness, blood pressure, insulin sensitivity, and triglycerides even when its direct effect on LDL is small.
After starting or changing a statin, clinicians commonly repeat a lipid panel within several weeks to a few months to confirm the expected response and adherence. If the LDL reduction is much smaller than expected, first check whether doses are being missed, whether the medicine was actually started, and whether secondary causes are present before simply escalating treatment.
Routine CK testing is not needed for everyone. CK is most useful when significant muscle symptoms or weakness occur. Liver tests are checked based on baseline history, symptoms, and clinical judgment. Blood glucose or A1C may be followed more closely in people at risk for diabetes.
A useful follow-up visit should answer three questions: Did LDL fall enough? Is the medicine tolerable? Has the patient’s overall risk changed? If LDL remains above goal, treatment can be intensified by increasing the statin dose, improving adherence, adding a nonstatin, or combining approaches.
Do not stop a statin because the cholesterol number looks “normal” after treatment. The number may be normal precisely because the medication is working. If the underlying cardiovascular risk remains, stopping can allow LDL to rise again.
Adherence matters more than many people realize. Missing an occasional dose is different from taking a statin only a few days each month, which can leave LDL substantially above the intended level. If daily dosing is difficult because of cost, forgetfulness, shift work, swallowing problems, or side effects, say so directly. The solution may be a generic alternative, a pill organizer, a simpler medication schedule, or a deliberately designed intermittent regimen for intolerance. Clinicians can only interpret a follow-up LDL correctly if they know how the medicine was actually taken. A surprising lab result is often a cue to troubleshoot the plan rather than assume the drug has failed.
Questions to Ask Before Starting or Stopping
A good statin discussion should be specific enough that you understand both the expected benefit and the backup plan if problems occur. Ask your clinician:
- Why are you recommending a statin for me? Is the reason prior cardiovascular disease, LDL level, diabetes, kidney disease, calculated risk, coronary calcium, or several factors together?
- What is my LDL goal and expected percentage reduction? Knowing both makes it easier to judge whether the dose is working.
- How much absolute benefit am I likely to get? People at higher baseline risk usually prevent more events.
- Which statin and dose fit my other medicines? Drug interactions can change the safest choice.
- What should I do if muscle symptoms develop? Agree on which symptoms can wait for a routine call and which need urgent evaluation.
- When will we repeat my lipid panel? A defined follow-up keeps treatment from drifting without reassessment.
- What happens if I cannot reach the goal on this dose? The answer may be a higher dose, another statin, or a nonstatin add-on.
If you are uncertain about starting treatment for primary prevention, ask whether additional risk information would change the decision. A coronary calcium score or selected biomarkers can sometimes turn an ambiguous choice into a clearer one. But if you already have a strong indication—such as established atherosclerotic disease or LDL around 190 mg/dL or higher—delaying effective therapy for repeated optional testing may not add value.
Statins have decades of outcome evidence, but they are not one-size-fits-all. The most useful approach is to match the intensity of treatment to the intensity of risk, monitor the response, address side effects systematically, and add or substitute other LDL-lowering therapies when needed. That keeps the focus where it belongs: reducing the chance of future cardiovascular events while making long-term treatment practical.
References
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines 2026 (Guideline)
- 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias 2025 (Guideline)
- Safety Profile of Statins: An Umbrella Review of Systematic Reviews and Meta-analyses 2026 (Umbrella Review)
- Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force [Internet] 2022 (Systematic Review)
- NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient 2022 (Position Statement)
- Statin-Associated Muscle Symptoms: Identification and Recommendations for Management. 2024 (Review)
Disclaimer
This article provides general education and does not replace individualized medical advice. Whether you should start, continue, change, or stop a statin depends on your cardiovascular risk, LDL level, other health conditions, medications, and treatment goals. Do not stop a prescribed statin without discussing a safe plan with your clinician, especially if you have known cardiovascular disease.





